Sanofi, Bristol shake up alliance as patents end
PARIS Oct 3 (Reuters) - Drugmakers Sanofi and Bristol-Myers Squibb said they plan to restructure their alliance from Jan. 1 to respond to the loss of exclusivity on two key drugs and the arrival of generic competition in many major markets.
The move will see Bristol-Myers return rights to blood clot preventer Plavix and blood pressure treatment Avapro to the French drugmaker in all markets, the companies said in a joint statement on Wednesday.
This will give Sanofi sole commercial control of the two treatments, although Bristol-Myers will keep rights to Plavix in the United States and Puerto Rico.
In return, Sanofi will pay Bristol-Myers royalty payments through 2018 on its sales of branded and unbranded Plavix worldwide, excluding the U.S. and Puerto Rico, and on sales of Avapro/Avalide.
Sanofi will also make a $200 million terminal payment to Bristol-Myers at the end of 2018, the companies said.
Plavix had been the world's second-biggest selling prescription medicine for several years with annual revenue reaching about $9 billion at its peak.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Last-minute Obamacare exemption for those with canceled plans
- Target cyber breach hits 40 million payment cards at holiday peak |
- New York Mayor-elect's reputation for lateness parodied on Twitter
- U.S. diplomats, but not prosecutors, seek to quell India dispute |